Teladoc Health, Inc. (NYSE:TDOC) Expected to Announce Earnings of -$0.71 Per Share

Wall Street brokerages expect Teladoc Health, Inc. (NYSE:TDOC – Get Rating) to post earnings per share of ($0.71) for the current quarter, according to Zacks Investment Research. Nine analysts have issued estimates for Teladoc Health’s earnings. The highest EPS estimate is ($0.61) and the lowest is ($1.13). Teladoc Health reported earnings of ($0.86) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 17.4%. The firm is scheduled to announce its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Teladoc Health will report full year earnings of ($43.18) per share for the current year, with EPS estimates ranging from ($44.16) to ($42.69). For the next year, analysts expect that the company will post earnings of ($1.60) per share, with EPS estimates ranging from ($3.16) to ($0.48). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that follow Teladoc Health.

Teladoc Health (NYSE:TDOC – Get Rating) last released its earnings results on Wednesday, April 27th. The health services provider reported ($41.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($41.00). Teladoc Health had a negative return on equity of 2.12% and a negative net margin of 321.94%. During the same period last year, the company earned $0.13 earnings per share.

Several research firms have issued reports on TDOC. Deutsche Bank Aktiengesellschaft dropped their price target on Teladoc Health from $78.00 to $44.00 in a report on Thursday, April 28th. Barclays cut their target price on shares of Teladoc Health from $77.00 to $45.00 in a research note on Thursday, April 28th. StockNews.com assumed coverage on shares of Teladoc Health in a research note on Thursday, March 31st. They set a “sell” rating on the stock. UBS Group cut their target price on shares of Teladoc Health from $130.00 to $72.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 8th. Finally, Robert W. Baird cut their target price on shares of Teladoc Health from $72.00 to $64.00 in a research note on Wednesday, April 27th. One analyst has rated the stock with a sell rating, nineteen have assigned a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $90.68.

In related news, SVP Andrew Turitz sold 1,754 shares of the stock in a transaction dated Thursday, March 3rd. The shares were sold at an average price of $70.24, for a total value of $123,200.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Mala Murthy sold 6,717 shares of the stock in a transaction dated Thursday, March 3rd. The stock was sold at an average price of $70.24, for a total transaction of $471,802.08. The disclosure for this sale can be found here. Insiders have sold 14,842 shares of company stock valued at $1,042,502 in the last ninety days. 1.55% of the stock is owned by company insiders.

A number of large investors have recently bought and sold shares of TDOC. Altshuler Shaham Ltd increased its holdings in shares of Teladoc Health by 15.4% during the third quarter. Altshuler Shaham Ltd now owns 750 shares of the health services provider’s stock worth $95,000 after buying an additional 100 shares in the last quarter. First Mercantile Trust Co. increased its holdings in shares of Teladoc Health by 1.1% during the third quarter. First Mercantile Trust Co. now owns 9,550 shares of the health services provider’s stock worth $1,211,000 after buying an additional 100 shares in the last quarter. Personal CFO Solutions LLC grew its stake in shares of Teladoc Health by 4.5% during the third quarter. Personal CFO Solutions LLC now owns 2,531 shares of the health services provider’s stock valued at $321,000 after purchasing an additional 110 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Teladoc Health by 5.2% during the fourth quarter. The Manufacturers Life Insurance Company now owns 2,766 shares of the health services provider’s stock valued at $254,000 after purchasing an additional 137 shares during the last quarter. Finally, Benjamin Edwards Inc. grew its stake in shares of Teladoc Health by 27.6% during the fourth quarter. Benjamin Edwards Inc. now owns 670 shares of the health services provider’s stock valued at $62,000 after purchasing an additional 145 shares during the last quarter. 87.17% of the stock is owned by hedge funds and other institutional investors.

Shares of NYSE TDOC traded down $0.17 during trading on Friday, hitting $32.74. The company had a trading volume of 5,053,111 shares, compared to its average volume of 15,402,974. The company has a market cap of $5.28 billion, a P/E ratio of -0.76 and a beta of 0.82. Teladoc Health has a 52 week low of $27.38 and a 52 week high of $174.32. The business’s 50-day moving average is $55.02 and its 200 day moving average is $77.14. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.71 and a current ratio of 3.94.

Teladoc Health Company Profile (Get Rating)

Teladoc Health, Inc provides virtual healthcare services in the United States and internationally. The company offers a portfolio of services and solutions covering non-urgent, episodic, chronic, and complicated medical conditions, including diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and mental health conditions.

Featured Articles